{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:15:29Z","timestamp":1784614529022,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11523-025-01134-8","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T19:04:37Z","timestamp":1740510277000},"page":"349-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma"],"prefix":"10.1007","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct03269136","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04798586","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04649359","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05014412","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9825-5890","authenticated-orcid":false,"given":"Mohamed","family":"Elmeliegy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Viqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Irby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hibma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Kei","family":"Lon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooneh","family":"Soltantabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Skoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"2","key":"1134_CR1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.18185","volume":"198","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Hungria V, Mohty M, Mateos M-V. How I treat triple-class refractory multiple myeloma. Br J Haematol. 2022;198(2):244\u201356.","journal-title":"Br J Haematol"},{"issue":"11","key":"1134_CR2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443\u20138.","journal-title":"Leukemia"},{"issue":"9","key":"1134_CR3","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari J, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"key":"1134_CR4","unstructured":"Pfizer. Elranatamab-bcmm (Elrexfio) [package insert]. New York (NY): Pfizer; 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19669. Accessed 5 Oct 2023."},{"key":"1134_CR5","unstructured":"European Medicines Agency. Elranatamab-bcmm (Elrexfio) [summary of product characteristics]. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elrexfio-epar-product-information_en.pdf. Accessed 15 Feb 2024."},{"key":"1134_CR6","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05020236?term=MagnetisMM-5&rank=1. Accessed 28 Nov 2023."},{"key":"1134_CR7","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05317416?term=MagnetisMM-7&rank=1. Accessed 28 Nov 2023."},{"key":"1134_CR8","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05623020?term=MagnetisMM-6&rank=1. Accessed 28 Nov 2023."},{"issue":"1","key":"1134_CR9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.","journal-title":"J Exp Clin Cancer Res"},{"key":"1134_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","volume":"8","author":"H Murthy","year":"2019","unstructured":"Murthy H, Iqbal M, Chavez JC, Kharfan-Dabaja MA. Cytokine release syndrome: current perspectives. Immunotarg Ther. 2019;8:43\u201352.","journal-title":"Immunotarg Ther."},{"issue":"27","key":"1134_CR11","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"SA Holstein","year":"2023","unstructured":"Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol. 2023;41(27):4416\u201329.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1134_CR12","doi-asserted-by":"crossref","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","volume":"15","author":"K Ball","year":"2023","unstructured":"Ball K, Dovedi SJ, Vajjah P, Phipps A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs. 2023;15(1):2181016.","journal-title":"MAbs"},{"issue":"6","key":"1134_CR13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.3223","volume":"115","author":"P Soltantabar","year":"2024","unstructured":"Soltantabar P, Sharma S, Wang D, Lon H-K, Czibere A, Hickmann A, et al. Impact of Treatment modality and route of administration on cytokine release syndrome in relapsed or refractory multiple myeloma: a meta-analysis. Clin Pharmacol Ther. 2024;115(6):1258\u201368.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1134_CR14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cpt.3361","volume":"116","author":"M Elmeliegy","year":"2024","unstructured":"Elmeliegy M, Chen J, Dontabhaktuni A, Gaudy A, Kapitanov GI, Li J, et al. Dosing strategies and quantitative clinical pharmacology for bispecific T-cell engagers development in oncology. Clin Pharmacol Ther. 2024;116(3):637\u201346.","journal-title":"Clin Pharmacol Ther"},{"key":"1134_CR15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","volume":"81","author":"H Chen","year":"2019","unstructured":"Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62\u20136.","journal-title":"Leuk Res"},{"key":"1134_CR16","doi-asserted-by":"crossref","first-page":"1450173","DOI":"10.3389\/fimmu.2024.1450173","volume":"15","author":"M Su","year":"2024","unstructured":"Su M, Chen L, Xie L, Fleurie A, Jonquieres R, Cao Q, et al. Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy. Front Immunol. 2024;15:1450173.","journal-title":"Front Immunol"},{"issue":"6","key":"1134_CR17","volume":"14","author":"T Gu","year":"2022","unstructured":"Gu T, Hu K, Si X, Hu Y, Huang H. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. WIREs Mech Dis. 2022;14(6): e1576.","journal-title":"WIREs Mech Dis."},{"issue":"4","key":"1134_CR18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1134_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy: assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl. 1","key":"1134_CR20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","volume":"37","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37(Suppl. 1):48\u201352.","journal-title":"Hematol Oncol"},{"key":"1134_CR21","unstructured":"Hibma J, Elmeliegy M, King LE, McCush F, Wang D, Willaims JH. Population pharmacokinetic analysis of elranatamab in patients with multiple myeloma. 2023; p.31: abstract 10648. http:\/\/www.page-meeting.org\/?abstract=10648. Accessed 14 Mar 2024."},{"key":"1134_CR22","doi-asserted-by":"publisher","unstructured":"Irby D, Hibma J, Elmeliegy M, Wang D, Vandendries E, Poels K, et al. A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients. Clinical Pharmacology & Therapeutics, 2025, electronically published ahead of print. https:\/\/doi.org\/10.1002\/cpt.3533.","DOI":"10.1002\/cpt.3533"},{"key":"1134_CR23","unstructured":"Janssen. Ciltacabtagene autoleucel (Carvykti) [package insert]. Horsham (PA): Janssen; 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf. Accessed 24 Oct 2023."},{"key":"1134_CR24","unstructured":"Bristol-Meyers Squib. Idecabtagene vicleucel (Abecma) [package insert]. Summit (NJ): Bristol-Meyers Squibb; 2021. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf. Accessed 24 Oct 2023."},{"key":"1134_CR25","unstructured":"Janssen. Teclistamab-cqyv (Tecvayi) [package insert]. Horsham (PA): Janssen; 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TECVAYLI-pi.pdf. Accessed 24 Oct 2023."},{"issue":"6","key":"1134_CR26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1134_CR27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"13","key":"1134_CR28","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","volume":"129","author":"TG Martin","year":"2023","unstructured":"Martin TG, Mateos MV, Nooka A, Banerjee A, Kobos R, Pei L, et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma. Cancer. 2023;129(13):2035\u201346.","journal-title":"Cancer"},{"issue":"10297","key":"1134_CR29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"2","key":"1134_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cpt.3308","volume":"116","author":"K Lim","year":"2024","unstructured":"Lim K, Zhu XS, Zhou D, Ren S, Phipps A. Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin Pharmacol Ther. 2024;116(2):315\u201327.","journal-title":"Clin Pharmacol Ther"},{"key":"1134_CR31","unstructured":"Janssen. Talquetamab-tgvs (Talvey) [package insert]. Horsham (PA): Janssen; 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TALVEY-pi.pdf. Accessed 24 Oct 2023."},{"key":"1134_CR32","unstructured":"FDA Center for Drug Evaluation and Research. Talquetamab-tgvs (Talvey) multi-discipline review. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761342Orig1s000MultidisciplineR.pdf. Accessed 22 Mar 2024."},{"issue":"9","key":"1134_CR33","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0091270009337512","volume":"49","author":"DD Wang","year":"2009","unstructured":"Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49(9):1012\u201324.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1134_CR34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/10600280231170650","volume":"58","author":"BL Erstad","year":"2024","unstructured":"Erstad BL, Davis LE. Fixed versus body-sized-based dosing of monoclonal antibodies. Ann Pharmacother. 2024;58(1):91\u20135.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1134_CR35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Girgis S, Goldberg JD. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"Suppl. 3","key":"1134_CR36","volume":"7","author":"C Touzeau","year":"2023","unstructured":"Touzeau C, Schinke C, Minnema M, van de Donk Niels WCJ, Rodriguez-Otero P, Mateos M-V, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (TAL), a GPRC5DxCD3 bispecific antibody (BsAb) for relapsed\/refractory mutltiple myeloma. HemaSphere. 2023;7(Suppl. 3): e5955094.","journal-title":"HemaSphere."},{"issue":"2","key":"1134_CR37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188\u201395.","journal-title":"Blood"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01134-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01134-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01134-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:13:00Z","timestamp":1743041580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01134-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01134-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"11 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Umberto Conte, Donald Irby, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Athanasia Skoura, Sibo Jiang, and Diane Wang report employment and stock ownership at Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"All studies reported here were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice. The study protocols and relevant documents were approved by independent institutional review boards or ethics committees at each investigative center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Upon reasonable request and subject to review, Pfizer will provide the data that support the findings of this article. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See  for more information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the trial conception\/design, or the acquisition, analysis, or interpretation of data. All authors contributed to the drafting of the manuscript and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}